ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Entry into a Material Definitive AgreementItem 9.01. Entry Into A Material Definitive Agreement.
On April3, 2018, Aralez Pharmaceuticals US Inc. (“Aralez US”), a Delaware company and a wholly-owned, indirect subsidiary of Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada, entered into a Modification of Contract (the “Contract Modification”) to which the United States of America (the “Government”) exercised its second renewal option under that certain VA National Contract, effective April29, 2016, between Aralez US (by novation from AstraZeneca Pharmaceuticals LP) and the Government (the “Agreement”), extending the term of the Agreement by one year to April28, 2019 on the same pricing terms as have been in effect during the April29, 2017 through April28, 2018 annual term except for a price decrease to the 200mg SKUs only (which are currently the smallest selling SKUs). Under the Agreement, Aralez US provides products containing metoprolol succinate (sold under the brand name Toprol-XL®) as the active pharmaceutical ingredient at fixed prices to the U.S. Department of Veterans Affairs and certain other United States federal government agencies. The Contract Modification is filed as Exhibit10.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d)List of Exhibits
|
EXHIBIT NO. |
DESCRIPTION |
|
10.1 |
Modification of Contract, executed on April3, 2018, between the United States of America and Aralez Pharmaceuticals US Inc. |